Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment

Abstract : A gold therapeutic nanoplatform with the same molecule used as reductant, coating and therapeutic agent has been developed in a one-pot, one-phase process using alendronate, a drug from the bisphosphonate family known for its antitumor effects. In addition, the core made of gold nanoparticles (NPs) brings thermal functionalities under irradiation within the first biological window (650-900 nm). The Au@alendronate nanoplatform thus provided a combined antitumor activity through drug delivery and photothermal therapy. Au@alendronate NPs inhibited in vitro the proliferation of prostate cancer cells (PC3) in a dose-dependent manner, with an IC 50 value of 100 µM. Under NIR irradiation a temperature increase was observed leading to a reduction of the IC 50 value to 1 µM, with total tumor cell death at 100 µM.
Document type :
Journal articles
Complete list of metadatas

Cited literature [46 references]  Display  Hide  Download

https://hal.utc.fr/hal-02192626
Contributor : Erwann Guénin <>
Submitted on : Wednesday, July 24, 2019 - 8:46:21 AM
Last modification on : Thursday, September 5, 2019 - 4:46:54 PM

File

sans-titre.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Anouchka Plan Sangnier, Romain Aufaure, Laurence Motte, Claire Wilhelm, Erwann Guénin, et al.. Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment. Beilstein Journal of Nanotechnology, Karlsruhe Institute of Technology., 2018, 9, pp.2947-2952. ⟨10.3762/bjnano.9.273⟩. ⟨hal-02192626⟩

Share

Metrics

Record views

46

Files downloads

46